Ocular Allergy Treatment Practical Impact Trial

To Assess the Impact of Ocular Allergy Treatment on Patients Using an Opthalmic Agent (or no Treatment) Versus Alcaftadine(Lastacaft™)

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01808768

Acronym

(OAT-PIT)

Enrollment

Registered

2013-03-11

Start date

2013-04-30

Completion date

2013-11-30

Last updated

2013-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Conjunctivitis, Rhinoconjunctivitis

Brief summary

To study the impact of alcaftadine in patients treated with other opthalmic ocular agents (or specific topical opthalmic treatment) in an allergy subspecialist outpatient setting.

Detailed description

To assess the impact of ocular allergy treatment on patients using an ophthalmic agent (or no treatment) versus alcaftadine(Lastacaft™)

Interventions

DRUGAlcaftadine

Alcaftadine 0.25% one dorp each eye daily for 1-2 weeks.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. patients age 18 and older with a history of seasonal or perennial forms of allergic conjunctivitis and skin test positive reactivity to seasonal aeroallergens 2. Total Ocular Symptom Score (TOSS) on the day of enrollment of 4 or more. 3. have allergic ocular symptoms for the past week for which they are either treating with ophthalmic agents or have had no treatment. 4. Are willing/able to follow instructions from the study investigator and his/her study staff. 5. Have signed infromed consent approved by Institutional Review Board or Independent Ethics Committee. \-

Exclusion criteria

1. Active ocular infection; 2. History of retinal detachment, diabetic neuropathy, or any progressive retinal disease; 3. Ocular surgical intervention within three (3) months prior to visit 1 or scheduled during the study. 4. History of unstable, or uncontrolled disease of any nature. 5. Pregnancy or lactation; 6. Have a known hypersensitivity tp LASTACAFT™ (alcaftadine) -

Design outcomes

Primary

Measure	Time frame
Quality of Life- Eye Allergy Patient Impact Questionnaire	4 months

Secondary

Measure	Time frame
Ocular Surface Disease Index Pollen Count correlation of symptoms	6 months

Countries

United States

Contacts

Primary ContactJayesh Kanuga, MD

jkanuga@gmail.com732-906-1747

Backup ContactErika Julca, LPN,CRC

ejulca1@gmail.com732-906-1747

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026